TYP
Director Trades
| Date | Director | Value |
|---|
Company News
Tryptamine Therapeutics advances psychedelic drug candidate TRP-8803 after positive safety review
Tryptamine Therapeutics (ASX: TYP) is preparing to move to the next stage of testing a psychedelic pro-drug compound after receiving positive feedback in the development of its TRP-8803 candidate for the treatment of eating disorders and other conditions. The Safety Review Council (SRC) response regarding the company’s ongoing Healthy Human Volunteer Study (Phase 1b) has […]
Tryptamine Therapeutics achieves milestone of world’s first IV-infused psilocin dosing
Recently-listed biotech company Tryptamine Therapeutics (ASX: TYP) has successfully completed the world’s first dosing of a patient with intravenous (IV)-infused psilocin (TRP-8803) in South Australia. The participant dosing of TRP-8803 is part of the company’s planned healthy human volunteer study at CMAX Clinical Research in Adelaide. Tryptamine is developing a scalable IV-infused psilocin formulation which […]